Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20629328 | 0.93 | EPHX1 (0.50) | EPHX1ALDH1A1SIGMAR1L3MBTL1 | |
| SCHEMBL17424948 | 0.91 | EPHX1 (0.54) | EPHX1SIGMAR1 | |
| SCHEMBL14018455 | 0.90 | EPHX1 (0.52) | EPHX1ALDH1A1SIGMAR1 | |
| SCHEMBL24042407 | 0.89 | EPHX1 (0.52) | EPHX1SIGMAR1 | |
| SCHEMBL22403813 | 0.88 | EPHX1 (0.56) | EPHX1ALDH1A1 | |
| SCHEMBL21398350 | 0.86 | EPHX1 (0.61) | EPHX1ALDH1A1 | |
| SCHEMBL18602993 | 0.84 | EPHX1 (0.38) | EPHX1 | |
| SCHEMBL22111696 | 0.83 | EPHX1 (0.56) | EPHX1ALDH1A1SIGMAR1L3MBTL1 | |
| SCHEMBL18685898 | 0.82 | EPHX1 (0.42) | EPHX1SIGMAR1 | |
| SCHEMBL20644846 | 0.81 | EPHX1 (0.61) | EPHX1ALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-11-17 | — | — | US | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| EP-3157942-B1 | SITE SPECIFIC PROTEIN MODIFICATIONS | NOVARTIS AG (CH) | 2020-06-17 | — | — | EP | disclosed |
| US-20190350932-A1 | PREPARATION AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-11-21 | — | — | US | disclosed |
| US-20190015417-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-01-17 | — | — | US | disclosed |
| WO-2017147410-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-1673087-B1 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES CO (US) | 2015-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190015417-A1 | THERAPEUTIC AGENT FOR FGFR INHIBITOR-RESISTANT CANCER | FGFR1, FGFR3, FGFR4 | EPHX1 2513/4885ALDH1A1 94/4885SIGMAR1 4807/4885 |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | ATG7, SQSTM1, BECN1 | EPHX1 4533/4885ALDH1A1 4264/4885SIGMAR1 3139/4885 |
| US-10835536-B2 | Therapeutic agent for FGFR inhibitor-resistant cancer | FGFR1, FGFR3, FGFR4 | EPHX1 2513/4885ALDH1A1 94/4885SIGMAR1 4807/4885 |
| US-20190350932-A1 | PREPARATION AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | FGFR3, FGFR1, FGFR4 | EPHX1 2024/4885ALDH1A1 1665/4885SIGMAR1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.